Skip to main content

SAB Biotherapeutics, Inc.

Monday, February 26, 2024
SAB Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing fully-human, multi-targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The company’s lead asset, SAB-142, targets Type-1 diabetes (T1D) with a disease-modifying therapeutic approach that aims at changing the treatment paradigm by delaying onset and potentially preventing disease progression. SAB-142: Type 1 Diabetes (T1D) - Fully human, broadly neutralizing immunoglobulin (hIgG) treatment being developed to delay the onset and progression of T1D with a mode of action similar to that of clinically validated rabbit-derived anti-thymocyte globulin (rATG or Thymoglobulin). First-in-class fully-human hIgG treatment aimed to provide superior safety for delaying onset and progression of clinical Stage 3 Type 1 Diabetes by eliminating risk of serum sickness and high immunogenicity.
Samuel Reich, Chairman and CEO - SAB Biotherapeutics


South Dakota


United States


CEO/Top Company Official

Eddie J. Sullivan, PhD Co-Founder, President & CEO

Lead Product in Development

SAB-142 for Type 1 Diabetes

Development Phase of Primary Product


Number Of Unlicensed Products

1. SAB-176 for Influenza. SAB recently received Fast Track Designation and Breakthrough Therapy Designation from the U.S. Food and Drug Administration for SAB-176, which targets multiple strains of influenza, based upon positive clinical data from a Phase 2a trial.

Double Helix


Supporting Bank Sponsor


Premier Sponsors

Conference Sponsors


Media Partner


Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.